Track topics on Twitter Track topics that are important to you
PAREXEL International Corporation, a leading global biopharmaceutical services provider, and Pamplona Capital Management, announced that they have entered into a definitive agreement under which Pamplona will acquire all of the outstanding shares of PAREXEL for $88.10 per share in cash in a transaction valued at approximately $5.0 billion, including PAREXEL’s net debt. The purchase price […]
The post PAREXEL International to be acquired by Pamplona Capital Management appeared first on CenterWatch News Online.
Original Article: PAREXEL International to be acquired by Pamplona Capital ManagementNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...